Erythropoietin: New horizon in cardiovascular medicine

Recent Patents on Cardiovascular Drug Discovery

Volumn 2, Issue 1, 2007, Pages 5-12

  Koul, Deepak ^a   Dhar, Sunil ^a   Chen Scarabelli, Carol ^a   Guglin, Maya ^a   Scarabelli, Tiziano M ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Anemia; Apoptosis; Erythropoietin; Heart failure; Ischemia; Myocardial infarction

Indexed keywords

CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FUROSEMIDE; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DIALYSIS; DRUG ACTIVITY; DRUG DOSE TITRATION; DRUG WITHDRAWAL; ENDOTHELIUM CELL; ERYTHROID CELL; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; REGULATORY MECHANISM; REPERFUSION INJURY; REVIEW; SINGLE DRUG DOSE;

ANIMALS; APOPTOSIS; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, ERYTHROPOIETIN;

EID: 34249311639     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489007779606112     Document Type: Review

References (108)

1. Wang GL, Jiang BH, Rue EA, et al. Hypoxia inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995; 92: 5510-5514.
2. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev 1992; 72: 449-489.
3. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. Am Soc Nephrol 1999; 10: 2392-395.
4. Young, P.R., Erickson-Miller, C.L.: US20006153190 (2000).
5. Low-Friedrich I, Grutzmacher P, Marz W, et al. Therapy with recombinant human EPO reduces cardiac size and improves heart function in chronic hemodialysis patients. Am J Nephrol 1991; 11: 54-60.
6. Mann JF. What are the short-term and long-term consequences of anaemia in CRF patients? Nephrol Dial Transplant 1999; 14 Suppl 2: 29-36.
7. Gaudard A, Varlet-Marie E, Bressolle F, et al. Drugs for increasing oxygen and their potential use in doping: a review. Sports Med 2003; 33: 187-212.
8. Volpe M, Tritto C, Testa U, et al. Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am J Cardiol. 1994; 74: 468-473.
9. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001; 37: 1775-1780.
10. Noakes TD. Tainted Glory - Doping and Athletic Performance. N Engl J Med 351: 847-849.
11. Morishita E, Masuda S, Nagao M, et al. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate- induced neuronal death. Neuroscience. 1997; 76: 105-116.
12. Sakanaka M, Wen TC, Matsuda S, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998; 95: 4635-4640.
13. Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003; 100: 4802-4806.
14. Siren AL, Fratelli M, Brines M, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA. 2001; 98: 4044-4049.
15. Chattopadhyay A, Choudhury TD, Bandyopadhyay D, et al. Protective effect of erythropoietin on the oxidative damage of erythrocyte membrane by hydroxyl radical. Biochem Pharmacol. 2000; 59: 419-425.
16. Ribatti D, Presta M, Vacca A, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood. 1999; 93: 2627-2636.
17. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci 1990; 87: 6934-6938.
18. Witthuhn A, Quelle FW, Silvennoinem O, et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993; 74: 227-236.
19. Balu, P.: US20046703480 (2004).
20. Gouilleux F, Pallard C, et al. Prolactin, growth Hormone, erythropoietin and granulocyte-macrophage colony stimulating factor induce MGF-Stat5 DNA binding activity. EMBO J 1995; 14: 2005-2013.
21. Bao H, Jacobs-Helber SM, Lawson AE, et al. Protein kinase B (c-Akt), phosphatidylinositol 3-kinase, and STAT5 are activated by erythropoietin (EPO) in HCD57 erythroid cells but are constitutively active in an EPO-dependent, apoptosis resistant aubclone. Blood 1999; 93: 3757-3773.
22. Cheung JY, Miller BA. Molecular mechanisms of erythropoietin signaling. Nephron 2001; 87: 215-222.
23. Digicayliglu M, Lipton SA. Erythropoietin-mediated neuro-protection involves cross-talk between jak2 and NF-KB signaling cascades. Nature 2001; 412: 641-647.
24. Ammarguellat F, Llovera M, et al. Low doses of EPO activate MAP kinase but not JAK2-STAT5 in rat vascular smooth muscle cells. Biochem Biophy Res Common 2001; 284: 1031-1038.
25. 2 channels: Activation by phospholipase C-gammal. Kidney Int 1998; 53: 1259-1268.
26. Miller BA, Cheung JY. Mechanisms of erythropoietin signal transduction: involvement of calcium channels. Proc Soc Exp Biol Med 1994; 206: 263-267.
27. Fraser JK, Lin FK, Berridge MV. Expression of high affinity receptors for erythropoietin on human bone marrow cells and on the human erythroleukemic cell line, Hel. Exp Hematol 1988; 16: 836-842.
28. Fraser JK, Tan AS, Lin F-K, et al. Expression of specific high-affinity binding sites for erythropoietin on rat and mouse megakaryocytes. Exp Hematol 1989; 17: 10-16.
29. Anagnostou A, Liu Z, Steiner M, et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994; 91: 3974-3978.
30. Nagai T, Akizawa T, Kohjiro S, et al. rHuEPO enhances the production of plasminogen activator inhibitor-1 in cultures endothelial cells. Proc Natl Acad Sci USA 1990; 87: 5978-5982.
31. Anagnostou A, Lee ES, et al. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990; 87: 5978-5982.
32. Ogilvie M, Yu X, Nicolas-Metral V, et al. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J Biol Chem 2000; 275: 39754-39761.
33. Masuda M, Nagao M, Takahata K, et al. Functional eryhtropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of the erythroid cells. J Biol Chem 1993; 268: 11208-11216.
34. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional eryhtropoietin receptors. Kidney Int 1999; 55: 808-820.
35. Arcasoy MO, Amin K, Karayal AF, et al. Functional significance of eryhthrpoietin receptor expression in breast cancer. Lab Invest 2002; 82: 911-918.
36. Junk AK, Mammis A, Savitz S, et al. Eryhtropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci USA 2002; 99: 10659-10664.
37. Wu H, Lee SH, Gao J, et al. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 1999; 126: 3597-3605.
38. Erbayraktar S, Yilmaz O, Gokmen N, et al. EPO is a multifunctional tissue-protective cytokine. Curr Hematol Rep 2003; 2: 465-470.
39. Nielsen, S., Frøkiær, J., Jonassen, T. E. N., Bjerke, T.: WO0182952A2 & A3 (2001).
40. Stuckmann I, Evans S, Lassar AB. EPO and retinoic acid, secreted from the epicardium, are required for cardiac myocyte proliferation. Dev Biol 2003; 255: 334-349.
41. Ratajczak J, Majka M, Kijowski J, et al. Biological significance of different erythropoietic factors secreted by normal human early erythroid cells. Leuk Lymphoma 2003; 44(5): (767-774).
42. Silva M, Grillot D, Benito A, et al. Erythropoietin can promote erythroid pro genitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood 1996; 88: 1576-1582.
43. Silva M, Benito A, Sanz C, et al. Erythropoietin can induce the expression of Bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem 1999; 274: 22165-22169.
44. Sakanaka M, Wen TC, Matsuda S, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998; 95: 4635-4640.
45. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med. 1997; 336: 1131-1141.
46. Saraste A, Pulkki K, Kallajoki M, et al. Apoptosis in human acute myocardial infarction. Circulation 1997; 95: 320-323.
47. Grimm C, Wenzel A, Groszer M, et al. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med 2002; 8: 718-724.
48. Celik M, Gokmen N, Erbayraktar S. EPO prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci USA 2002; 99: 2258-2263.
49. Gorio A, Gokmen N, Erbayraktar S, et al. Recombinant human EPO counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA 2002; 99: 9450-455.
50. Chong ZZ, Kang JQ, Maiese K. Apaf-1, Bcl-xL, cytochrome c, and caspase-9 form the critical elements for cerebral vascular protection by erythropoietin. J cereb Blood Flow Metab. 2003; 23: 320-330.
51. Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002; 106: 2973-979.
52. Wang L, Zhang Z, Wang Y. Treatment of stroke with EPO enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004; 35: 1732-737.
53. Siren AL, Fratelli M, Brines M. EPO prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 2001; 98: 4044-4049.
54. Bianchi R, Buyukakilli B, Brines M. EPO both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci USA 2004; 101: 823-828.
55. Junk AK, Mammis A, Savitz SI. EPO administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci USA 2002; 99: 10659-10664.
56. Bahlmann FH, Song R, Boehm SM, et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004; 110: 1006-1012.
57. Juul SE, Yachnis AT, Christensen RD. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 1998; 52: 235-249.
58. Van der Meer P, Lipsic E, Boer RA, et al. A functional erythropoietin receptor in a rat heart is linked to anti-apoptotic effects. J Am Coll Card 2003; 41: 330A.
59. Wu H, Lee SH, Gao J, Liu X, et al. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 1999; 126: 3597-3605.
60. Amann K, Neimeier KA, Schwarz U, et al. Rats with moderate renal failure show capillary deficit in heart but not skeletal muscle. Am J Kidney Dis 1997; 30: 382-388.
61. Anagnostou A, Liu Z, Steiner M, et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994; 91: 3974-3978.
62. Ashley RA, Dubuque SH, Dvorak B, et al. Erythropoietin stimulates vasculogenesis in neonatal rat mesenteric microvascular endothelial cells. Pediatr Res 2002; 51: 472-478.
63. Carlini RG, Reyes AA, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 1995; 47: 740-745.
64. Jaquet K, Krause K, Tawakol-Khodai M, et al. Erythropoietin and VEGF exhibit equal angiogenic; potential. Microvasc Res 2002; 64: 326.
65. Jelkmann W, Hellwig-Burgel T. Biology of erythropoietin. Adv Exp Med Biol 2001; 502: 169-187.
66. De Boer RA, Henning RH, Tio RA, et al. Identification of a specific pattern of downregulation in expression of isoforms of vascular endothelial growth factor in dilated cardiomyopathy. Heart 2002; 88: 412-414.
67. Van Veldhuisen DJ, van den Heuvel AF, Blanksma PK, et al. Ischemia and left ventricular dysfunction: a reciprocal relation? J Cardiovasc Pharmacol 1998; 1(32 Suppl): S46-S51.
68. De Boer RA, van Veldhuisen DJ, van der Wijk J, et al. Additional use of immunostaining for active caspase 3 and cleaved actin and PARP fragments to detect apoptosis in patients with chronic heart failure. J Card Fail 2000; 6: 330-337.
69. Shi Q, Rafii S, Wu MHD, et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998; 92: 362-367.
70. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85: 221-228.
71. Sterin-Borda L, Barcelo AC, Bozzini CE. EPO improves cardiac contractility in post-hypoxic mice. Br J Haematol 2003; 121: 180-186.
72. Moon C, Krawczyk M, Ahn D, et al. EPO reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA 2003; 100: 11612-11617.
73. Van der Meer P, Lipsic E, Henning RH, et al. Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Ent J Heart Fail. 2004; 6: 853-859.
74. Calvillo L, Latini R, Kajstura J, et al. Recombinant human EPO protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003; 100: 4802-806.
75. Abdelrahman M, Sharples EJ, McDonald MC, et al. Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 2004; 22: 63-69.
76. Parsa CJ, Matsumoto A, Kim J, et al. A novel protective effect of EPO in the infarcted heart. J Clin Invest 2003; 112: 999-1007.
77. Parsa CJ, Kim J, Riel RU, et al. Cardioprotective effects of EPO in the reperfused ischemic heart: A potential role for cardiac fibroblasts. J Biol Chem 2004; 279: 20655-662.
78. Lipsic E, van der Meer P, Henning RH, et al. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol 2004; 44: 473-479.
79. Fiordaliso F, Chimenti S, Staszewsky L, et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci USA 2005; 102: 2046-2051.
80. Webster KA, Discher DJ, Kaiser S, et al. Hypoxia-activated apoptosis of cardiac myocytes requires reoxygenation or a pH shift and is independent of p53. J Clin Invest 1999; 104: 239-252.
81. Scarabelli T, Stephanou A, Rayment N, et al. Apoptosis of endothelial cells precedes myocyte cell apoptosis in ischemia/ reperfusion injury. Circulation 2001; 104: 253-256.
82. Thompson, L. H.: US20067078376 (2006).
83. Okonko, DO, Anker SD. Anemia in chronic heart failure: pathogenetic mechanisms. J Card Fail 2004; 10: S5-S9.
84. Silverberg DS, Wexler D, Iaina A. The importance of anemia and its correction in the management of severe congestive heart failure. Eur J Heart Fail 2002; 4: 681-86.
85. Van der Meer P, Voors AA, Lipsic E, et al. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 2004; 44: 63-67.
86. Silverberg D. Outcomes of anemia management in renal insufficiency and cardiac disease. Nephrol Dial Transplant 2003; 18: ii7-ii12.
87. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous EPO and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000; 35: 1737-744.
88. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 2003; 107: 223-25.
89. Anand I, McMurray JJ, Whitmore J. Anemia and its relationship to clinical outcome in heart failure. Circulation 2004; 110: 149-54.
90. Felker GM, Gattis WA, Leimberger JD. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol. 2003; 92: 625-628.
91. Katz SD. Mechanisms and treatment of anemia in chronic heart failure. Congest Heart Fail 2004; 10: 243-247.
92. Caiola K, Cheng JW. Use of erythropoietin in heart failure management. Ann Pharmacother. 2004; 38: 2145-49.
93. McBride BF, White CM. Anemia management in heart failure: a thick review of thin data. Pharmacotherapy 2004; 24: 757-67.
94. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001; 38: 955-62.
95. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous EPO and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001; 37: 1775-780.
96. Silverberg DS, Wexler D, Blum M, et al. EPO should be part of congestive heart failure management. Kidney Int Suppl 2003; S40-47.
97. Silverberg DS, Wexler D, Blum B, et al. Anemia in chronic kidney disease and congestive heart failure. Blood Purif 2003; 21: 124-130.
98. Silverberg DS, Wexler D, Blum M, et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous EPO and intravenous iron. Nephrol Dial Transplant 2003; 18: 141-46.
99. Mancini DM, Katz SD, Lang CC, et al. Effect of EPO on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003; 107: 294-299.
100. Mitka M. Researchers probe anemia-heart failure link. JAMA 2003; 290: 1835-38.
101. George J, Goldstein E, Abashidze A, et al. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. Cardiovasc Res. 2005; 68: 299-306.
102. Desai A, Zhao Y, Lankford HA, et al. Nitric oxide suppresses EPO-induced monocyte chemoattractant protein-1 in endothelial cells: implications for atherogenesis in chronic renal disease. Lab Invest 2006; 86: 369-79.
103. Fyhrquist F, Karppinen K, Honkanen T, et al. EPO levels are normalized during treatment of congestive heart failure with enalapril. J Intern Med 1989; 226: 257-60.
104. Volpe M, Tritto C, Testa U, et al. Blood levels of EPO in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am J Cardiol 1994; 74: 468-73.
105. Plata R, Cornejo A, Arratia C, et al. Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial. Lancet 2002; 359: 663-66.
106. Erturk S, Nergizoglu G, Ates K, et al. The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients. Nephrol Dial Transplant 1999; 14: 1912-16.
107. Cruz DN, Perazella MA, Abu-Alfa AK, et al. Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: any evidence of EPO resistance? Am J Kidney Dis 1996; 28: 535-40.
108. Albitar S, Genin R, Fen-Chong M, et al. High dose enalapril impairs the response to EPO treatment in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 1206-1210.